Akos Czibere
- Oncology top 2%
- Molecular Biology top 10%
- Hematology top 1%
- Pulmonary and Respiratory Medicine top 5%
- Cancer Research top 5%
- Co-authors
- Rainer HaasIngmar BrunsGuido KobbeRoland FenkTowia A. LibermannFabian ZohrenLuiz F. ZerbiniUlrich Germing
- Topics
- PARP inhibition in cancer therapy (30 papers)Acute Myeloid Leukemia Research (23 papers)BRCA gene mutations in cancer (15 papers)
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Akos Czibere
111 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 1.2k
- Molecular Biology 1.0k
- Hematology 804
- Pulmonary and Respiratory Medicine 545
- Cancer Research 344
Countries citing papers authored by Akos Czibere
This map shows the geographic impact of Akos Czibere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akos Czibere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akos Czibere more than expected).
Fields of papers citing papers by Akos Czibere
This network shows the impact of papers produced by Akos Czibere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akos Czibere. The network helps show where Akos Czibere may publish in the future.
Co-authorship network of co-authors of Akos Czibere
This figure shows the co-authorship network connecting the top 25 collaborators of Akos Czibere. A scholar is included among the top collaborators of Akos Czibere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akos Czibere. Akos Czibere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialbreakdown → | 252 |
| 3 | 44 | |
| 4 | 18 | |
| 5 | 30 | |
| 6 | 30 | |
| 7 | 32 | |
| 8 | 12 | |
| 9 | 19 | |
| 10 | 11 | |
| 11 | 75 | |
| 12 | 11 | |
| 13 | 21 | |
| 14 | 22 | |
| 15 | 29 | |
| 16 | 31 | |
| 17 | 48 | |
| 18 | 11 | |
| 19 | 9 | |
| 20 | 40 |
About Akos Czibere
Akos Czibere is a scholar working on Hematology, Oncology and Genetics, having authored 112 papers that have together received 2.6k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (30 papers), Acute Myeloid Leukemia Research (23 papers) and BRCA gene mutations in cancer (15 papers). The work is most often cited by research in Hematology (804 citations), Oncology (1.2k citations) and Genetics (273 citations). Akos Czibere has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Rainer Haas, Ingmar Bruns, Guido Kobbe, Roland Fenk, Towia A. Libermann, Fabian Zohren, Luiz F. Zerbini, Ulrich Germing, Thomas Schroeder and Wolf Christian Prall. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.